38 results about "Sugar moiety" patented technology

The present disclosure provides enzymes and methods of using those enzymes to transfer sugar moieties to the substrate steviol glycosides. The designed beta-1, 3-glycosyltransferase can be used for adding a glucose monomer connected with beta-1, 3 to steviol glycosides. In particular, the designed beta-1, 3-glycosyltransferase is used in a one-pot reaction together with a beta-1, 2-glycosyltransferase and a sucrose synthase to convert stevioside and / or Reb A to Reb M.

Oligomeric compounds (including those that are antisense agents or portions thereof) are provided that comprise a modified oligonucleotide having at least one modified internucleoside linking group.SOLUTION: By an oligomeric compound comprising a modified oligonucleotide consisting of 12 to 70 linked nucleosides linked via internucleoside linking groups, wherein at least one nucleoside comprises a modified sugar moiety and wherein at least one internucleoside linking group is a phosphodiester or phosphorothioate internucleoside linking group.SELECTED DRAWING: Figure 1

Methods are provided for attaching a mannose-binding C-type lectin receptor targeting moiety to a polymeric carbohydrate scaffold using an amide bond, which can be found between a leash, such as an amine-terminated leash, and the mannose-binding C-type lectin receptor targeting moiety. The disclosed compounds and compositions utilizing this amide bond provide highly stable compounds that significantly reduce loss of the mannose-binding C-type lectin receptor targeting moiety from the polymeric carbohydrate scaffold.

Described herein are novel oligosaccharides of cannabidiol and other cannabinoids and methods of production and uses thereof. The production method includes contacting cannabidiol with UDP-carbohydrate dependent glycosyltransferases (UGT73A class) to produce a cannabinoid-β-D-glycoside, then contacting the product with a cyclomaltodextrin glucanotransferase and a cyclodextrin to elongate the sugar moiety with (1-4)-α-D-glucopyranoside, thereby producing a mixed 0-a-structure in a recombinant host that has an amphiphilic structure as a surfactant solubilizer and different enzymatic degradability of α- and β-D-glucopyranose residues by amylases and β-glycosidases, thereby allowing targeted drug delivery.

Provided herein is a noninvasive method for measuring pH, glucose and glycogen levels using a single acquisition method, as well as systems for performing the method. This method for glycogen / glucose (and pH) detection has high specificity enabled by superior chemical shift separation in high-strength magnetic fields. The methods have applications in detecting changing tumor microenvironments in cancerous cells for measuring important metrics for noninvasive and quantitative metabolic profiling.

The present invention provides a single-stranded antisense oligonucleotide or pharmaceutically acceptable salt thereof for regulating the expression and / or function of the ATXN7 gene. In the single-stranded antisense oligonucleotide, each nucleotide is bonded by a phosphate group and / or modified phosphate group. The single-stranded antisense oligonucleotide includes a gap region, a 3' wing region bonded to the 3' terminal of the gap region, and a 5' wing region bonded to the 5' terminal of the gap region. The gap region is a deoxyribose-constituted nucleic acid in which a nucleic acid modified by a sugar moiety may be included. The 3' wing region and the 5' wing region are modified nucleic acids. The sugar modification constituting the single-stranded antisense oligonucleotide is a modified nucleic acid represented by formula (A1). The single-stranded antisense oligonucleotide has a base length of 12-30 mer. The base sequence of the antisense oligonucleotide is: a base sequence having a sequence identity of 90-100% with a base sequence that is complementary to at least one target region constituted at the same base length as the antisense oligonucleotide in the base sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5; a base sequence that is complementary to the base sequence obtained by deleting, substituting, inserting, or adding one or more bases in the target region; or a base sequence that, under stringent conditions, hybridizes with an oligonucleotide having the target region.

The present disclosure provides enzymes and methods of using those enzymes to transfer sugar moieties to substrate steviol glycosides. Specifically, designed beta-1,2-glycosyltransferases and sucrose synthases are used in one-pot reactions to convert stevioside and Reb A to Reb E and Reb D. Additionally, designed beta-1,2-glycosyltransferases can be used in one-pot reactions with sucrose synthases and beta-1,3-glycosyltransferases to produce Reb M from stevioside and / or Reb A.

The disclosure provides a polyene. The polyene comprises two sugar moieties and / or is modified in an exocyclic carboxylic acid position, or is a pharmaceutically acceptable salt, solvate, tautomeric form or polymorphic form thereof. In some embodiments, the polyene is a compound of formula I. The disclosure extends to pharmaceutical and agrochemical compositions, preservatives and foodstuffs comprising the polyene. The disclosure also extends to the polyene or pharmaceutical composition for use as a medicament, for use in treating, preventing or ameliorating an infection or a prion disease and methods of treating a disease in a plant or a mushroom using the polyene. The disclosure further provides a method of producing a polyene comprising a sugar moiety and / or a modification at an exocyclic carboxylic acid thereon. Finally, the disclosure also extends to a recombinant organism or cell expressing a glycosyltransferase enzyme or an amidotransferase enzyme.

The present disclosure relates to a composition including one or more modified nucleotide, wherein the modified nucleotide comprises a purine or pyrimidine base and a sugar moiety having a 3′-hydroxy blocking group, and a radical scavenger, wherein the composition is lyophilised. The present disclosure further relates to a composition including one or more functional protein; one or more functional protein activator; and one or more non-reducing sugar, wherein the composition is lyophilised. Also disclosed are methods of rehydration of one or more compositions described herein and kits including one or more compositions described herein. Further disclosed are cartridges including a flow cell comprising one or more reagent reservoirs, where the one or more reagent reservoirs include one or more compositions described herein.

To provide compounds, compositions and methods for modulating splicing of SMN2.SOLUTION: In certain embodiments, the present disclosure provides oligomeric compounds comprising or consisting of modified oligonucleotides having one or more 2'-O-(N-alkyl acetamide) or 2'-O-(N-methyl acetamide) modified sugar moieties and complementary to SMN pre-mRNA. Also provided are uses of the compounds and compositions in the manufacture of a medicament for treatment of spinal muscular atrophy.SELECTED DRAWING: None

The present invention provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLP1 RNA in cells or subjects, and, in some cases, the amount of proteolipid protein 1 in cells or subjects. [Solution] The present invention provides an oligomeric compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the nucleic acid base sequence of the modified oligonucleotide is at least 85% complementary to equal-length portions of the PLP1 nucleic acid, and the modified oligonucleotide comprises at least one modification selected from modified sugar moieties and modified nucleoside-to-nucleoside bonds. Such compounds, methods, and pharmaceutical compositions are useful for improving at least one symptom or characteristic of leukodystrophy.

The present disclosure provides enzymatic methods for the production of 3'-phosphatenucleoside-5'-triphosphate (NQP). The present disclosure further provides enzymatic methods for the production of nucleotide-5'-triphosphates. In some embodiments, a method of producing a nucleotide triphosphate with a phosphate group at the 3' position of the sugar moiety (NQP), the method comprising at least: contacting a nucleoside diphosphate (NDP) with a nucleoside diphosphate kinase, a 3' -O-kinase, and a phosphate donor under reaction conditions such that a NTP with a phosphate group on the 3' position of the sugar moiety (NQP) is produced.

High yield separation and purification of one or more cannabinoid glycoside species from a complex mixture of cannabinoids. In one preferred aspect, the novel systems and methods of the invention can separate one or more cannabinoids and / or cannabinoid glycoside species from a complex mixture, and preferably a quantity of cannabidiol (CBD) glycosides having two UDP-sugar moieties from a complex mixture of CBD and CBD-glycosides having one UDP-sugar moiety.

The present invention relates to a chemically modified oligonucleotide comprising a sequence of 23 to 80 nucleotides in length, a target sequence capable of binding to a target RNA, a central base triad (CBT) comprising three nucleotides (I) wherein the central nucleotide (N0) is directly opposed to a target adenosine in the target RNA, and wherein the core oligonucleotide comprises the following sequence (II): wherein the core oligonucleotide comprises the following sequence (II); the sequences comprise different 2'sugar moiety modifications and bond modifications. The disclosure also provides oligonucleotides and compositions thereof for treating or preventing a genetic disorder, condition, or disease. Also provided are methods for editing a target adenosine or deaminating at least one specific adenosine in a target nucleic acid. 5 '-

The invention relates to novel silicon-based fluoride acceptor groups (SiFA groups) of the following formulae, as well as to compounds suitable for use in radiopharmacy comprising such groupswherein R1 and R2 are each a linear or branched C3 to C10 alkyl group and R3 is selected from (i) —OH or —O−, (ii) a sugar moiety or an amino sugar moiety, (iii) an amino acid moiety or an oligopeptide moiety, (iv) a PEG moiety; and from combinations of two or more of (ii), (iii) and (iv).

The invention provides a method for introducing a nanoparticle (100) into a prokaryotic cell (10), wherein the method comprises exposing the prokaryotic cell (10) to the nanoparticle (100), wherein: the nanoparticle (100) has an equivalent spherical diameter selected from the range of -20 nm; the nanoparticle (100) comprises a single-chain polymer nanoparticle (101); the nanoparticle (100) comprises a backbone (110), a plurality of intramolecular crosslinks (120), and a plurality of side groups (130) bound to the backbone (110); wherein the backbone (110) comprises n backbone atoms, wherein the n backbone atoms comprise ≥ 0.9*n carbon atoms; each intramolecular crosslink (120) covalently interconnects two backbone locations (112) of the backbone (110); k of the plurality of side groups (130) comprise ligand moieties (140) selected from the group comprising sugar moieties, a glycerol moiety, an acetate moiety, a pyruvate moiety, a lactate moiety, a succinate moiety, amino acid moieties, and fatty acid moieties, wherein k / n is selected from the range of 0.05-0.49; the prokaryotic cell (10) comprises a receptor (14) configured to interact with one or more of the ligand moieties (140).

Modified red blood cells (RBCs) including one or more surface proteins or lipids covalently linked to a cargo by click chemistry are provided. In some examples, the cargo is a cancer therapeutic agent, an autoimmune antigen, or an antigen of a bacterial or viral agent. Also provided are methods of treating a subject with a disease or disorder with the modified RBCs or methods of treating a subject with a disease or disorder or performing imaging analysis of a subject, including administering to the subject a composition including an azido-modified sugar moiety, thereby generating red blood cells comprising one or more azido-labeled surface proteins and administering to the subject a composition including a cargo for treating or inhibiting the disease or disorder, wherein the cargo is capable of covalently binding to the one or more azido-labeled surface proteins or lipids.

Provided are methods of attaching a mannose-binding C-type lectin receptor targeting moiety to a polymeric carbohydrate backbone using an amide linkage. The amide linkage may be found between a leash, such as an amine terminated leash, and the mannose-binding C-type lectin receptor targeting moieties. The compounds and compositions disclosed utilizing the amide linkage provide for highly stable compounds with a significant reduction in loss of mannose-binding C-type lectin receptor targeting moieties from the polymeric carbohydrate backbone.

The present invention relates to an agent for use in decreasing the level of intracellular phosphorylated tau in neurons, which agent can bind ELAVL4 with a binding affinity of at least - 8.0 kcal / mol. The agent comprises a structural element selected from the group consisting of a steroid backbone, a sugar moiety by glycosidic linkage, an O-linked glucuronide, and a lactone group and is suitably selected from the group of porphyrins, macrolactams, macrolides, vitamin D glucuronides, steroid glucuronides, withanolides, cardenolide glycosides, anthracyclines, ergoloid mesylates, ergotamines and derivates thereof, biphenyls, and piperazines. The administration of said agent leads to a decrease in protein levels of phosphorylated tau in normal neurons treated with the agent as compared to non-treated normal neurons and to a decrease in the Aβ42 / Aβ40 ratio in fAD neurons treated with the agent as compared to non-treated fAD neurons. The agent is administered for the treatment of a tauopathy, which may be involved in Alzheimer's disease, frontotemporal dementia, Parkinson's disease or progressive supranuclear palsy and multiple sclerosis.

Described herein are polysaccharide polymers comprising a sugar moiety modified with a hydroxyl modifier (e.g., a sugar monomer of formula (I)), as well as related compositions, hydrogels, implantable elements, and methods of use thereof.

The present invention belongs to the field of biomedicine, and specifically relates to an siRNA, its antibody conjugate, product and application. The sense strand of the siRNA of the present invention is the sequence shown in SEQ ID NO: 17, and the antisense strand is the sequence shown in SEQ ID NO: 18; the present invention also provides an siRNA antibody conjugate prepared by a site-specific conjugation method, including an antibody, a linker and siRNA, and the siRNA is preferably a modified siRNA; the modified nucleotide is selected from one or more of 2'-position sugar moiety modification, phosphate group modification or nucleotide analogue modification. The siRNA antibody conjugate of the present invention can reduce the expression of DMPK mRNA in human skeletal muscle cells HSKMC and human bladder transitional cell papilloma cells RT4, and has great significance for the treatment of DM1 type myotonic dystrophy disease.

The invention belongs to the technical field of molecular biology, and particularly relates to template conversion oligonucleotide, a kit and application of the template conversion oligonucleotide. In the first aspect of the invention, a template conversion oligonucleotide is provided, the template conversion oligonucleotide comprises a template conversion region at the 3'end, the template conversion region comprises a plurality of nucleotides, the nucleotides comprise sugars and basic groups, and the basic groups are guanine; wherein in the plurality of nucleotides, the 3 '-hydroxyl site of the glycosyl of the nucleotide at the 3'-terminal is provided with a modification for preventing the 3 '-hydroxyl from forming a phosphodiester bond. TSO of conventional reverse transcription is specifically modified, then conventional reverse transcription processes of single cells, space-time omics and the like are carried out, additional enrichment operation is not needed, and the operation process is simple. Not only is the data utilization rate of single molecule sequencing improved, but also the sensitivity of target gene capture is improved, and background interference is reduced.

The present invention relates to a chemically modified oligoribonucleotide for use in site-directed A-to-1 editing of a target RNA inside a cell with endogenous ADAR, comprising a sequence with a length from 25 to 80 nucleotides, capable of binding to a target sequence in the target RNA, comprising a Central Base Triplet of 3 nucleotides with the central nucleotide opposite to the target adenosine in the target RNA which is to be edited to an inosine, having a) at least 90% of the pyrimidine nucleosides outside the Central Base Triplet are chemically modified, either at the 2′ position of the sugar moiety or as deoxyribonucleosides, or a combination thereof, b) no more than 6 consecutive nucleosides are chemically modified with 2′-O-methyl at the 2′ position of the sugar moiety, c) at least two of the three nucleosides of the Central Base Triplet are chemically modified at the 2′ position of the sugar moiety, or are deoxyribonucleosides,

Disclosed are polypeptides and methods of glycosylating the C19 hydroxyl group of AmdeB (i.e., amphotericin B lacking the sugar moiety) comprising contacting AmdeB with a saccharide in the presence of one of the polypeptides. The methods access compounds that are analogues of amphotericin B with a modified sugar moiety that have an improved therapeutic index, such as C2′epiAmB. Also disclosed are pharmaceutical compositions comprising the compounds and a pharmaceutically acceptable carrier.

Described herein are polysaccharide polymers that include sugar moieties (e.g., sugar monomers of formula (I)) that have been modified with a hydroxyl modifier, as well as related compositions, hydrogels, implantable elements, and methods of use thereof.

The present invention provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of APP RNA in cells or animals, and, in some cases, for reducing the amount of APP protein in cells or animals. [Solution] The present invention provides an oligomeric compound comprising a modified oligonucleotide having a specific base sequence, wherein the nucleic acid base sequence of the modified oligonucleotide is at least 80% complementary to the isolength portion of the APP nucleic acid, and the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified nucleoside bond. Such compounds, methods, and pharmaceutical compositions are useful for improving at least one symptom or feature of a neurodegenerative disease or disorder.

This specification describes polymers containing specific hydroxyl group modifications, as well as related compositions and methods thereof. [Solution] This specification describes polysaccharide polymers comprising sugar moieties (e.g., sugar monomers of formula (I)) modified with hydroxyl modifiers, as well as related compositions, hydrogels, implantable elements, and methods of use thereof.

It relates to a composition, preferably for cleansing and / or removing makeups from keratin materials, comprising: (i) N-acyl alanine and / or salts thereof; (ii) at least one surfactant with at least one sugar moiety; and (iii) at least 2 wt.% of at least one oil, relative to the total weight of the composition. It also relates to a process for cleansing and / or removing makeups from keratin materials, in particular the skin, comprising applying to the keratin materials, in particular the skin, of the composition mentioned above, and rinsing off the composition after an optional period of time.

The invention relates to modified antisense oligonucleotides suitable for editing an adenosine in a target nucleic acid to inosine (A-to-I editing), wherein the oligonucleotide comprises: (I) a nucleic acid sequence of 25 to 70 nucleotides (nt) that is an antisense sequence substantially complementary to the target nucleic acid, (II) a central base triplet (CBT) (5'- N+1 e N0 f N-1 g -3') with the central nucleotide (N0) directly opposite the target adenosine to be edited when the antisense oligonucleotide is hybridised to the target nucleic acid, and (III) the following core sequence: 5'- a N+4 b N+3 c N+2 d N+1 e N0 f N-1 g N-2 h N-3 i N-4 j N-5 k N-6 l N-7 m N-8 n N-9 -3';and wherein: (a) at least two of the three nucleotides of the CBT are chemically modified at the 2' position of the sugar moiety, are deoxyribonucleosides, or a combination thereof and wherein d and e are internucleoside linkage modifications; (b) the N-2 nucleotide carries a 2'-O-alkyl- modification; and wherein the N-3 nucleotide carries a 2´-fluoro (2'-F)-modification; (c) at least 10% of nucleotides of the oligonucleotide are 2'-F-modified and at least 10% of nucleotides of the oligonucleotide are 2'-O-alkyl-modified, wherein no more than 6 consecutive nucleotides have the same 2'-modification; and wherein the oligonucleotide comprises one or more nucleotide mismatches outside the CBT that is / are not complementary to the corresponding position in the target nucleic; and wherein the mismatch is: at position -7 (N-7), wherein there is a G or C directly 3' to the mismatch and an A or U directly 5' to the mismatch; at position -9 (N-9), wherein there is a G or C directly 3' to the mismatch and an A or U directly 5' to the mismatch; or at position -9 (N-9), wherein there is a G or C directly 3' to the mismatch and an A or U directly 5' to the mismatch, and at position +2 (N+2).

The present invention relates to an agent for use in decreasing the level of intracellular phosphorylated tau in neurons, which agent can bind ELAVL4 with a binding affinity of at least - 8.0 kcal / mol. The agent comprises a structural element selected from the group consisting of a steroid backbone, a sugar moiety by glycosidic linkage, an O-linked glucuronide, and a lactone group and is suitably selected from the group of porphyrins, macrolactams, macrolides, vitamin D glucuronides, steroid glucuronides, withanolides, cardenolide glycosides, anthracyclines, ergoloid mesylates, ergotamines and derivates thereof, biphenyls, and piperazines. The administration of said agent leads to a decrease in protein levels of phosphorylated tau in normal neurons treated with the agent as compared to non-treated normal neurons and to a decrease in the Aβ42 / Aβ40 ratio in fAD neurons treated with the agent as compared to non-treated fAD neurons. The agent is administered for the treatment of a tauopathy, which may be involved in Alzheimer's disease, frontotemporal dementia, Parkinson's disease or progressive supranuclear palsy and multiple sclerosis.